COPD Foundation Ensures Patient Perspectives Included in ICER Review of New COPD Therapy
As an organization dedicated to improving the lives of individuals affected by chronic obstructive pulmonary disease (COPD), the COPD Foundation recognizes the critical importance of including patient perspectives in the review processes for new medical treatments. Our approach to the collaboration with ICER on the review of ensifentrine exemplifies how patient perspectives can inform and enhance a value assessment process.
Over the course of ICER's review of ensifentrine, the COPD Foundation provided patient-centric, evidence-based comments and feedback each step of the way. On June 14, ICER held a virtual public meeting where an independent council deliberated on the clinical effectiveness, broader benefits, long-term value, and policy considerations for the new therapy. The inclusion of COPD Foundation Board members Valerie Chang and Phyliss DiLorenzo ensured that the patient voice on these topics was heard loud and clear. Their contributions helped to underscore the daily challenges faced by patients and highlighted the potential benefits of new medications.
We believe the insights provided by the COPD Foundation and its members have contributed meaningfully to ICER's evaluation and appreciate the opportunity to help deliver patient perspectives.
"The COPD Foundation is committed to advocating for the inclusion of patients in all aspects of healthcare decision-making," said Dr. David Mannino, Chief Medical Officer of the COPD Foundation. "The Foundation will continue to support efforts that prioritize the needs and perspectives of those living with COPD, ensuring that their experiences guide the future of COPD treatment and care. We look forward to continuing our work with regulators, health plans, and others to ensure that new treatments meet the needs of the COPD community."
###
About the COPD Foundation
The COPD Foundation is a nonprofit organization whose mission is to help millions of people live longer and healthier lives by advancing research, advocacy, and awareness to stop COPD, bronchiectasis, and NTM lung disease. The Foundation does this through scientific research, education, advocacy, and awareness to prevent disease, slow progression, and find a cure. For more information, visit copdfoundation.org, or follow us on Twitter and LinkedIn.
Contact
Crystal Rothhaar
(786) 749-7104 x468
mediarelations@copdfoundation.org